Latest & greatest articles for Renin Angiotensin System

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on Renin Angiotensin System or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on Renin Angiotensin System and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for Renin Angiotensin System

41. Effect of inhibition of the renin-angiotensin system on development of type 2 diabetes mellitus (meta-analysis of randomized trials)

Effect of inhibition of the renin-angiotensin system on development of type 2 diabetes mellitus (meta-analysis of randomized trials) Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2007 DARE.

42. The impact of suppressing the renin-angiotensin system on atrial fibrillation

The impact of suppressing the renin-angiotensin system on atrial fibrillation Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2006 DARE.

43. Renin-angiotensin system inhibition prevents type 2 diabetes mellitus - part 1: a meta-analysis of randomised clinical trials

Renin-angiotensin system inhibition prevents type 2 diabetes mellitus - part 1: a meta-analysis of randomised clinical trials Renin-angiotensin system inhibition prevents type 2 diabetes mellitus - part 1: a meta-analysis of randomised clinical trials Renin-angiotensin system inhibition prevents type 2 diabetes mellitus - part 1: a meta-analysis of randomised clinical trials Scheen A J CRD summary This review assessed the effects of renin-angiotensin system (RAS) inhibition on the development (...) of type 2 diabetes in patients with arterial hypertension or congestive heart failure. The author concluded that RAS inhibition may help prevent type 2 diabetes. Given the lack of a quality assessment and the insufficient reporting of the review methods, the reliability of the author's conclusions cannot be adequately assessed. Authors' objectives To assess the effects of renin-angiotensin system (RAS) inhibition on the incidence of new cases of type 2 diabetes mellitus (T2DM) in patients

2004 DARE.

44. Genetic variation in the renin-angiotensin system and abdominal adiposity in men: the Olivetti Prospective Heart Study. (Abstract)

Genetic variation in the renin-angiotensin system and abdominal adiposity in men: the Olivetti Prospective Heart Study. The renin-angiotensin system is involved in adipocyte growth and differentiation and possibly in adipose tissue metabolism.To investigate the association of polymorphism in the angiotensin-converting enzyme (ACE) I/D gene, angiotensinogen M235T gene, and angiotensin II type 1 receptor A1166C gene with body mass index, body fat pattern, and obesity-associated hypertension.Cross (...) -sectional longitudinal study.The Olivetti factories in Marcianise and Pozzuoli, suburbs of Naples, Italy.959 adult men, 25 to 75 years of age.Renin-angiotensin system polymorphism, anthropometric indexes, blood pressure, and serum glucose and insulin levels.No association was detected between angiotensinogen or angiotensin II type 1 receptor gene polymorphism and anthropometric indexes or blood pressure. For ACE I/D polymorphism, significant age-genotype interaction was detected on cross-sectional

2003 Annals of Internal Medicine

45. Chronic renal diseases: renoprotective benefits of renin-angiotensin system inhibition. (Abstract)

Chronic renal diseases: renoprotective benefits of renin-angiotensin system inhibition. Progression to renal parenchymal damage and end-stage renal disease, which seems to be largely independent of the initial insult, is the final common pathway for chronic, proteinuric nephropathies in animals and humans. The key event is enhanced glomerular capillary pressure; this impairs glomerular permeability to proteins and permits excessive amounts of proteins to reach the lumen of the proximal tubule (...) . The secondary process of reabsorption of filtered proteins can contribute to renal interstitial injury by activating intracellular events, including upregulation of the genes encoding vasoactive and inflammatory mediators. Both interstitial inflammation and progression of disease can be controlled by such drugs as angiotensin-converting enzyme inhibitors, which strengthen the glomerular permeability barrier to proteins and thereby limit proteinuria and filtered protein-dependent inflammatory signals

2002 Annals of Internal Medicine

46. Randomised controlled trial of dual blockade of renin-angiotensin system in patients with hypertension, microalbuminuria, and non-insulin dependent diabetes: the candesartan and lisinopril microalbuminuria (CALM) study. Full Text available with Trip Pro

Randomised controlled trial of dual blockade of renin-angiotensin system in patients with hypertension, microalbuminuria, and non-insulin dependent diabetes: the candesartan and lisinopril microalbuminuria (CALM) study. To assess and compare the effects of candesartan or lisinopril, or both, on blood pressure and urinary albumin excretion in patients with microalbuminuria, hypertension, and type 2 diabetes.Prospective, randomised, parallel group, double blind study with four week placebo run

2000 BMJ Controlled trial quality: predicted high